Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

This Research Topic is the second volume of the “Exploring Immunological Tolerance in Allergy Treatment through AIT” Community Series. Please see Volume I ...

From regularly hoovering to drying your clothes inside, here’s what you can do to keep symptoms at bay this summer ...

The global allergy immunotherapy market is projected to grow from USD 3.7 billion in 2025 to USD 5 billion by 2035, registering a CAGR of 3.5%, according to Future Market Insights on 22 May 2025. This ...

Aptar Digital Health announces the positive results from the SPEED (1) survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer’s sublingual liquid ...

While sublingual immunotherapy is widely used for other allergens like pollen, dust mites, and grass, it has not yet been developed or approved for peanuts.

Curex's at-home Sublingual Immunotherapy (SLIT) program Food allergies are on the rise, likely due to extremely clean environments and early avoidance diets that prevent early exposure to allergens.

While the concept of sublingual immunotherapy is not novel, Curex is at the forefront of efforts to make it more accessible to the general public.

Children with histories of reactions, large SPT results or high serum-specific IgE were candidates. Buildup with sublingual immunotherapy lasted 1 to 2 years before an oral food challenge.

Although sublingual immunotherapy (SLIT) has become an effective treatment option for many allergies, about 20–30% of patients don't respond to SLIT for Japanese cedar pollinosis—a highly ...

Two main types of immunotherapy are used to treat allergic conjunctivitis: sublingual immunotherapy (SLIT) in the form of tablets and subcutaneous immunotherapy (SCIT) in the form of injections.